DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepointNo anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Dr. Zaks is the former Chief Medical Officer of Moderna, where he led development of their mRNA vaccine against the SARS-CoV-2 virus ... D capabilities in engineering of proteins, mRNAs, and lipid ...

2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit returns to unite 140+ biopharma thought ...

Research identifies how viral respiratory infection damages macrophages and suggests treatment with a pre-existing FDA approved drug.

Dr. Zaks is the former Chief Medical Officer of Moderna, where he led development of their mRNA vaccine against the SARS-CoV-2 virus. He previously held senior leadership positions in drug ...

Nanomedicine involves the use of nanoscale materials, such as biocompatible nanoparticles and nanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism. The utility ...

Insights into antibiotic–carrier interactions in the silk-fibroin-based nanoparticles and considerations on the formulation process greenness are limited. Hence, this work developed and characterized ...

Dr. Zaks is the former Chief Medical Officer of Moderna, where he led development of their mRNA vaccine against the SARS-CoV-2 virus. He previously held senior leadership positions in drug development ...

2020). In the last few years, the production of selenium nanoparticles (SeNPs) has attracted significant interest owing to their enhanced bioavailability, improved therapeutic efficacy, and reduced ...

Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States ...